Related Experiment Video
Updated: Aug 7, 2026
10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Biomarkers in Parkinson's disease
E Ray Dorsey1, Robert G Holloway, Bernard M Ravina
1University of Rochester Medical Center, 1351 Mt. Hope Avenue, Suite 223, Rochester, NY 14620, USA. ray.dorsey@ctcc.rochester.edu
Expert Review of Neurotherapeutics
|June 21, 2006
Summary
Parkinson's disease (PD) diagnosis relies on clinical assessment. While biomarkers show promise for early detection and treatment, their practical use in trials and patient care remains limited.
Area of Science:
- Neurodegenerative diseases
- Biomarker research
- Clinical trial methodology
Background:
- Parkinson's disease (PD) is a prevalent neurodegenerative disorder primarily diagnosed through clinical evaluation.
- Biomarkers, indicators of biological processes, hold potential for PD risk identification, therapy screening, diagnosis, and management optimization.
- Despite significant promise, the clinical utility of biomarkers in Parkinson's disease trials and practice is currently limited.
Purpose of the Study:
- To review the current state and potential applications of biomarkers in Parkinson's disease.
- To highlight the challenges hindering the widespread clinical adoption of PD biomarkers.
- To discuss the future directions for biomarker development and implementation in Parkinson's disease.
Main Methods:
- Literature review of existing studies on Parkinson's disease biomarkers.
- Analysis of biomarker performance in clinical trials and practice.
- Synthesis of current challenges and future opportunities in PD biomarker research.
Main Results:
- Biomarkers show potential in various aspects of Parkinson's disease management, including early detection and therapeutic response.
- Significant limitations exist in the translation of promising biomarkers into routine clinical use for Parkinson's disease.
- Current diagnostic and management strategies for Parkinson's disease heavily rely on clinical assessment.
Conclusions:
- Further research and validation are crucial to enhance the clinical utility of biomarkers in Parkinson's disease.
- Overcoming current limitations will enable biomarkers to significantly improve the diagnosis and management of Parkinson's disease.
- The integration of robust biomarkers is essential for advancing Parkinson's disease research and patient care.
Related Concept Videos
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...